Trial Profile
Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Mar 2024
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
- Indications Anal cancer; Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 08 May 2020 Status changed from active, no longer recruiting to completed.
- 20 Dec 2019 Planned End Date changed from 8 Mar 2020 to 9 Mar 2020.
- 20 Dec 2019 Planned primary completion date changed from 8 Mar 2020 to 9 Mar 2020.